Competition getting stiff for DPP-4 inhibitors
Published: 2011-09-30 06:57:00
Updated: 2011-09-30 06:57:00
Following Bristol-Myers Squibb’s Onglyza (saxagliptin), Boehringer Ingelheim finally won the approval of the Korea Food and Drug Administration for their diabetes drug Trajenta (linagliptin), a dipeptidyl peptidase 4 (DPP-4) inhibitor that will directly compete with Merck's fast-growing treatment...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.